Pfizer Taps Into Cytos’ Vaccine Pipeline
Licensing deal for $10 million upfront includes access to novel Immunodrug technology that uses virus like particles.
Licensing deal for $10 million upfront includes access to novel Immunodrug technology that uses virus like particles.